Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998
To the Editor.—The study by Dr Burge
and colleagues1 helps to establish that
in the debate over the possible risks of hypoglycemia with sulfonylureas,
a concern should not be the drug but rather the recipient. Indeed, the characteristic
of the patients with type 2 diabetes mellitus included in the study is highlighted
by a simple key word, healthy. Exclusion criteria
were the presence of severe cardiovascular, gastrointestinal, renal, or hepatic
disease, malignancies, or concurrent medications. Quite the contrary, the
typical patient with type 2 diabetes is not a healthy one.
Gambassi G, Carbonin P, Bernabei R. Hypoglycemia From Glipizide and Glyburide. JAMA. 1998;279(18):1441–1443. doi:10-1001/pubs.JAMA-ISSN-0098-7484-279-18-jac80006
Customize your JAMA Network experience by selecting one or more topics from the list below.